Uncover key drivers, emerging technologies, and competitive movements shaping the psoriasis biosimilars market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present And Forecasted Size Of The Psoriasis Biosimilars Market?

The psoriasis biosimilars market has experienced significant expansion in recent years. This market is projected to increase from $7.32 billion in 2024 to $8.16 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 11.5%. The historical growth of the market can be attributed to several factors, including the increasing cost burden associated with original biologics, the successful clinical outcomes and safety data provided by early market entrants, the broadening of indications beyond psoriasis, the rising global prevalence of chronic diseases, and modifications in hospital procurement policies.

The psoriasis biosimilars market size is anticipated to undergo significant expansion over the next few years. It is projected to increase to $12.43 billion by 2029, achieving a compound annual growth rate (CAGR) of 11.1%. This projected growth can be attributed to several factors during the forecast period, including the rising global incidence of psoriasis, the introduction of switching policies and interchangeability laws, advancements in biosimilar manufacturing, enhanced patient and physician education, and the implementation of bundled pricing and value-based contracts. Prominent trends expected in the forecast period encompass innovative biosimilar manufacturing platforms, AI-driven patient stratification, the launch of advanced drug delivery devices, the development of next-generation formulations, and the formation of strategic industry partnerships.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27399&type=smp

What Underlying Factors Are Supporting The Psoriasis Biosimilars Market Growth?

Elevated diagnosis rates for psoriatic arthritis are projected to drive the expansion of the psoriasis biosimilars market in the future. Psoriatic arthritis is defined as a persistent autoimmune disorder characterized by inflammation of the joints and skin, frequently observed in individuals who have previously had psoriasis. The rates of psoriatic arthritis diagnosis are on the rise, primarily attributed to enhanced screening methods among psoriasis patients. These improved protocols facilitate earlier and more precise diagnosis by identifying subtle joint symptoms that might have gone undetected previously. Psoriasis biosimilars aid in the management of psoriatic arthritis by offering cost-effective alternatives to existing biologic treatments, thereby effectively alleviating joint inflammation and skin manifestations. For example, as reported in May 2024 by the National Institutes of Health (NIH), a US-based government agency, psoriatic arthritis (PsA) in 2022 showed a prevalence of 0.221% and an incidence rate of 13.54 per 100,000 people. Consequently, the escalating rates of psoriatic arthritis diagnoses are fueling the expansion of the psoriasis biosimilars market.

How Does The Psoriasis Biosimilars Market Differ By Segment?

The psoriasis biosimilars market covered in this report is segmented

1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars

2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis

3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars

2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars

3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars

4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars

5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars

What New Opportunities Are Emerging From Trends In The Psoriasis Biosimilars Market?

Leading companies within the psoriasis biosimilars market are concentrating on bringing forth novel solutions, specifically biosimilars for plaque psoriasis, with the aim of increasing access to treatment, lowering healthcare expenditures, and bettering patient results. These biosimilars, designed for plaque psoriasis, serve as more affordable, highly comparable alternatives to existing approved biologic medications that manage this chronic autoimmune skin condition, which presents as red, scaly patches. An example of this is the launch in May 2025 by Sandoz Group AG, a Switzerland-based firm specializing in generic pharmaceuticals and biosimilars, of the Pyzchiva autoinjector. This product represents the first ustekinumab biosimilar autoinjector to become commercially available. Pyzchiva has received approval for treating adults suffering from plaque psoriasis, psoriatic arthritis, and Crohn’s disease, alongside pediatric patients who are six years of age or older (and weigh over 60 kg) with plaque psoriasis. Developed to improve patient adherence and overall quality of life, the autoinjector incorporates features such as precise automatic dosing, minimized injection discomfort, a compact build, and adaptable storage choices, all contributing to easier self-administration.

Who Are The Global Leaders Steering The Psoriasis Biosimilars Market Forward?

Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Merck & Co. Inc., Amgen Inc., Biogen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Samsung Bioepis Co. Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Torrent Pharmaceuticals Ltd., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Reliance Life Sciences Pvt. Ltd., and Alvotech hf.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/psoriasis-biosimilars-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Psoriasis Biosimilars Market?

North America was the largest region in the psoriasis biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27399&type=smp

Browse Through More Reports Similar to the Global Psoriasis Biosimilars Market 2025, By The Business Research Company

Connected Rail Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/connected-rail-global-market-report

Freight Railcar Parts Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/freight-railcar-parts-global-market-report

Cross Laminated Timber Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cross-laminated-timber-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model